Insider Transactions in Q1 2021 at Jounce Therapeutics, Inc. (JNCE)
Insider Transaction List (Q1 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 31
2021
|
Elizabeth Trehu Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
8,300
-8.15%
|
$83,000
$10.09 P/Share
|
|
Mar 31
2021
|
Elizabeth Trehu Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
8,300
+7.53%
|
$33,200
$4.02 P/Share
|
|
Mar 30
2021
|
Elizabeth Trehu Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
100
-0.11%
|
$1,000
$10.0 P/Share
|
|
Mar 30
2021
|
Elizabeth Trehu Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
100
+0.11%
|
$400
$4.02 P/Share
|
|
Mar 29
2021
|
Elizabeth Trehu Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
5,100
-5.17%
|
$51,000
$10.09 P/Share
|
|
Mar 29
2021
|
Elizabeth Trehu Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,100
+4.91%
|
$20,400
$4.02 P/Share
|
|
Mar 15
2021
|
John Duncan Higgons Director |
SELL
Open market or private sale
|
Direct |
200
-1.98%
|
$2,400
$12.8 P/Share
|
|
Mar 11
2021
|
Cary Pfeffer Director |
SELL
Other acquisition or disposition
|
Indirect |
0
|
-
|
|
Mar 11
2021
|
Third Rock Ventures Ii, L.P. > 10% Shareholder |
SELL
Other acquisition or disposition
|
Direct |
1,250,000
-16.13%
|
-
|
|
Mar 01
2021
|
Cary Pfeffer Director |
SELL
Open market or private sale
|
Indirect |
0
|
-
|
|
Mar 01
2021
|
Third Rock Ventures Ii, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
1,450,000
-15.76%
|
$15,950,000
$11.75 P/Share
|
|
Feb 16
2021
|
John Duncan Higgons Director |
SELL
Open market or private sale
|
Direct |
200
-1.94%
|
$2,200
$11.78 P/Share
|
|
Feb 03
2021
|
Richard /Ca/ Murray Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,500
+3.26%
|
-
|
|
Feb 01
2021
|
Hugh M Cole Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
26,700
+26.54%
|
-
|
|
Feb 01
2021
|
Kimberlee C Drapkin President, CFO and Treasurer |
BUY
Grant, award, or other acquisition
|
Direct |
22,250
+25.38%
|
-
|
|
Feb 01
2021
|
Richard /Ca/ Murray Director |
BUY
Grant, award, or other acquisition
|
Direct |
75,000
+25.83%
|
-
|
|
Feb 01
2021
|
Elizabeth Trehu Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
22,250
+19.21%
|
-
|
|
Jan 22
2021
|
Hugh M Cole Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
18,000
-27.61%
|
$198,000
$11.95 P/Share
|
|
Jan 22
2021
|
Hugh M Cole Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+7.4%
|
$50,000
$5.48 P/Share
|
|
Jan 21
2021
|
Richard /Ca/ Murray Director |
SELL
Open market or private sale
|
Direct |
33,518
-19.28%
|
$402,216
$12.06 P/Share
|
|
Jan 21
2021
|
Richard /Ca/ Murray Director |
BUY
Exercise of conversion of derivative security
|
Direct |
33,518
+16.16%
|
$0
$0.48 P/Share
|
|
Jan 21
2021
|
Kimberlee C Drapkin President, CFO and Treasurer |
SELL
Open market or private sale
|
Direct |
3,799
-8.09%
|
$45,588
$12.0 P/Share
|
|
Jan 21
2021
|
Kimberlee C Drapkin President, CFO and Treasurer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,799
+7.48%
|
$7,598
$2.36 P/Share
|
|
Jan 21
2021
|
John Duncan Higgons Director |
SELL
Open market or private sale
|
Direct |
200
-1.9%
|
$2,200
$11.11 P/Share
|
|
Jan 20
2021
|
Kimberlee C Drapkin President, CFO and Treasurer |
SELL
Open market or private sale
|
Direct |
26,201
-21.08%
|
$288,211
$11.03 P/Share
|
|
Jan 20
2021
|
Kimberlee C Drapkin President, CFO and Treasurer |
BUY
Exercise of conversion of derivative security
|
Direct |
13,501
+6.43%
|
$13,501
$1.19 P/Share
|
|
Jan 20
2021
|
John Duncan Higgons Director |
SELL
Open market or private sale
|
Direct |
1,500
-12.49%
|
$18,000
$12.0 P/Share
|
|
Jan 20
2021
|
Elizabeth Trehu Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
6,500
-8.35%
|
$78,000
$12.01 P/Share
|
|
Jan 20
2021
|
Elizabeth Trehu Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,500
+7.71%
|
$26,000
$4.02 P/Share
|
|
Jan 20
2021
|
Richard /Ca/ Murray Director |
SELL
Open market or private sale
|
Direct |
16,482
-10.51%
|
$197,784
$12.04 P/Share
|
|
Jan 20
2021
|
Richard /Ca/ Murray Director |
BUY
Exercise of conversion of derivative security
|
Direct |
16,482
+9.51%
|
$0
$0.48 P/Share
|
|
Jan 19
2021
|
Richard /Ca/ Murray Director |
SELL
Open market or private sale
|
Direct |
40,000
-22.18%
|
$360,000
$9.59 P/Share
|
|
Jan 19
2021
|
Richard /Ca/ Murray Director |
BUY
Exercise of conversion of derivative security
|
Direct |
40,000
+18.15%
|
$0
$0.48 P/Share
|
|
Jan 15
2021
|
Richard /Ca/ Murray Director |
SELL
Open market or private sale
|
Direct |
30,000
-17.61%
|
$240,000
$8.54 P/Share
|
|
Jan 15
2021
|
Richard /Ca/ Murray Director |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+14.97%
|
$0
$0.48 P/Share
|
|
Jan 08
2021
|
Hugh M Cole Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
3,340
-5.71%
|
$23,380
$7.0 P/Share
|
|
Jan 08
2021
|
Kimberlee C Drapkin President, CFO and Treasurer |
SELL
Open market or private sale
|
Direct |
3,130
-5.3%
|
$21,910
$7.0 P/Share
|
|
Jan 08
2021
|
Richard /Ca/ Murray Director |
SELL
Open market or private sale
|
Direct |
11,816
-7.76%
|
$82,712
$7.0 P/Share
|
|
Jan 08
2021
|
Elizabeth Trehu Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,846
-3.84%
|
$19,922
$7.0 P/Share
|
|
Jan 07
2021
|
Hugh M Cole Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
2,879
-4.69%
|
$17,274
$6.76 P/Share
|
|
Jan 07
2021
|
Kimberlee C Drapkin President, CFO and Treasurer |
SELL
Open market or private sale
|
Direct |
2,697
-4.37%
|
$16,182
$6.76 P/Share
|
|
Jan 07
2021
|
Richard /Ca/ Murray Director |
SELL
Open market or private sale
|
Direct |
10,183
-6.27%
|
$61,098
$6.76 P/Share
|
|
Jan 07
2021
|
Elizabeth Trehu Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,452
-3.2%
|
$14,712
$6.76 P/Share
|